Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ether doai
Patent
1995-06-06
1997-10-07
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ether doai
568624, A61K 31075, C07C 4311
Patent
active
056749112
ABSTRACT:
The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but substantially reduce the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable and the cardiotoxicity inherent in the native copolymers is substantially reduced.
REFERENCES:
patent: 2674619 (1954-04-01), Lundsted
patent: 2854378 (1958-09-01), Buckwalter et al.
patent: 2979528 (1961-04-01), Lundsted
patent: 3022335 (1962-02-01), Lundsted
patent: 3036118 (1962-05-01), Jackson et al.
patent: 3089818 (1963-05-01), Stone
patent: 3140232 (1964-07-01), Noseworthy
patent: 3228834 (1966-01-01), Gans et al.
patent: 3391196 (1968-07-01), Earing et al.
patent: 3450502 (1969-06-01), Hymes
patent: 3577522 (1971-05-01), Hymes
patent: 3590125 (1971-06-01), Hymes
patent: 3641240 (1972-02-01), Hymes et al.
patent: 3740421 (1973-06-01), Schmolka
patent: 3867521 (1975-02-01), Miskel et al.
patent: 3867533 (1975-02-01), Schmolka
patent: 3956259 (1976-05-01), Garcia et al.
patent: 3980772 (1976-09-01), Ginger et al.
patent: 4073886 (1978-02-01), Kehm
patent: 4100271 (1978-07-01), Krezanoski
patent: 4104455 (1978-08-01), Nagasawa
patent: 4179337 (1979-12-01), Davis et al.
patent: 4186253 (1980-01-01), Yokoyama et al.
patent: 4305922 (1981-12-01), Rhodes
patent: 4323560 (1982-04-01), Baschang et al.
patent: 4395393 (1983-07-01), Schmolka
patent: 4407790 (1983-10-01), Oakes et al.
patent: 4409209 (1983-10-01), Baschang et al.
patent: 4410660 (1983-10-01), Straus
patent: 4423038 (1983-12-01), Baschang et al.
patent: 4489158 (1984-12-01), Straus
patent: 4575484 (1986-03-01), Straus
patent: 4600652 (1986-07-01), Solomon et al.
patent: 4606918 (1986-08-01), Allison et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4764567 (1988-08-01), Ott
patent: 4801452 (1989-01-01), Hunter et al.
patent: 4837014 (1989-06-01), Hunter et al.
patent: 4837083 (1989-06-01), Hunter et al.
patent: 4879109 (1989-11-01), Hunter
patent: 4897263 (1990-01-01), Hunter
patent: 4937070 (1990-06-01), Hunter
patent: 4997644 (1991-03-01), Hunter
patent: 5017370 (1991-05-01), Hunter et al.
patent: 5028599 (1991-07-01), Hunter
patent: 5030448 (1991-07-01), Hunter
patent: 5032394 (1991-07-01), Hunter
patent: 5039520 (1991-08-01), Hunter
patent: 5041288 (1991-08-01), Hunter
patent: 5047236 (1991-09-01), Hunter et al.
patent: 5064643 (1991-11-01), Hunter et al.
patent: 5071649 (1991-12-01), Hunter
patent: 5078995 (1992-01-01), Hunter et al.
patent: 5080894 (1992-01-01), Hunter et al.
patent: 5089260 (1992-02-01), Hunter et al.
Schmolka, I., "A Review of Block Polymer Surfactants", Journal of American Oil Chemists Society, 54, No. 3, pp. 110-116 (1977).
Rodeheaver, G.T., "Pluronic.RTM. F-68: A Promising New Skin Wound Cleanser", Ann Emerg Med, 9:11, pp. 572-576 (1980).
Moore, A.R., et al., "Reduction of Splenic Vascular Resistance During Profusion by Pluronic.RTM. F-68", Journal of Surgical Research, Vo.. 8, pp. 563-566 (1968).
Benner, K.U., et al., "Cold-Induced Platelet Aggregation In Vivo And Its Inhibition By A Nonionic Surface Active Substance", Thrombosis Research, vol. 2, pp. 331-342 (1973).
Hymes, A.C., et al., "The Influence Of An Industrial Surfactant Pluronic.RTM. F-68, In The Treatment of Hemorrhagic Shock", Journal of Surgical Research, vol. 11, pp. 191-197 (1971).
Hoie, J., et al., "Effects of Pluronic.RTM. F-68, Poloralkol, On Vascular Resistance in Vivo", Journal of Surgical Research, vol. 11, pp. 515-517 (1971).
Grover, F.L., et al., "A nonionic Surfactant And Blood Viscosity", Arch. Surg., vol. 106, pp. 307-310 (1973).
Grover, F.L., et al., "The Effect of Pluronic.RTM. F-68 On Circulatory Dynamics And Renal and Carotid Artery Flow During Hemorrhagic Shock", Journal of Surgical Research, vol. 17, pp. 30-35 (1974).
Ketchum, L.D., et al., "Experimental Use of Pluronic.RTM. F-68 In Microvascular Surgery", Plastic and Reconstructive Surgery, vol. 53, pp. 288-292 (1974); Ketchum, L. D., Experimental Use of Pluronic F-68 in Microvascular Surgery, Plastic Reconstructive Surgery, vol. 54, p. 478 (October 1974).
Block and Graft Copolymerization, vol. 2, (ed. by R. J. Ceresa, John Wiley & Sons, 1976), "The Applications of Block Copolymer Polyol Surfactants", L. G. Lundsted and I. R. Schmolka; pp. 174-205 and pp. 255-272 (references).
Reindorf, C.A., et al., "Perfluorocarbon Compounds: Effects on the Rheological Properties of Sickle Erythrocytes in vitro", American Journal of Hematology, vol. 19, pp. 229-236 (1985).
Padilla, F., et al., "Effect of Fluorocarbon Emulsions on the Mechanical Fragility of Normal and Sickle Cells: In Vitro Studies" Federation Proceedings, vol. 34, pp. 1510-1512 (1975).
Vercellotti, G. M., et al., "Activation of Plasma Complement by Perfluorocarbon Artificial Blood: Probable Mechanism of Adverse Pulmonary Reactions in Treated Patients and Rationale for Corticosteroid Prophylaxis", Blood, vol. 59, pp. 1299-1304 (1982).
Janoff, A. S., et al., "The Modification of Human Erythrocyte Membrane Structure by Membrane Stabilizers: An Electron Spin Resonance Study", American Journal of Hematology, vol. 10, pp. 171-179 (1981).
Ketchum, L. D., "Pharmacological Alterations in the Clotting Mechanism: Use in Microvascular Surgery", Journal of Hand Surgery, vol. 3, pp. 407-415 (1978).
Vasko, K. A., et al., "Poloxalkol.RTM. (Pluronic F-68): A Priming Solution for Cardiopulmonary Bypass", Trans. Am. Soc. Artif. Int. Organs, 18, 526-531 (1972).
Block, N. L., et al., "Acutely Traumatized Canine Ureter: Effects of Low Molecular Weight Dextran and Surfactant Pluronic F-68", Urology, vol. III 190-194 (1974).
Knize, D. M., et al., "Use of Antisludging Agents in Experimental Cold Injuries", Surgery, Gynecology & Obstetrics, vol. 129, pp. 1019-1026 (1969).
Organ Perfusion and Preservation, (ed. by Norman, J. C., Appleton-Century-Crofts,)1968), Paton, B.C., et al., "The Use of a Nonionic Detergent Added to Organ Perfusates", pp. 105-120.
Smillie, J. A., et al., "Cryopreservation of Human Platelets with Polyvinylpyrrolidone", Transfusion, vol. 21, pp. 552-556 (1981).
Gaehtgens, P., et al., "Disaggregation of Human Red Blood Cells by Various Surface-Active Agents as Related to Changes of Cell Shape and Hemolysis", Act Heamat., vol. 33, pp 82-89 (1975).
Advances in Blood Substitute Research (ed. by Bolin, et al., Alan R. Liss, Inc. New York (1983) Sugi, et al., The Use of Fluosol-DA (FDA) in Emergency Situations: A report of 67 clinical cases, Abstract/451.
Lane, T. A., et al., "Reduction in the Toxicity of a Component of an Artificial Blood Substitute by Supercritical Fluid Fractionation", Transfusion, vol. 28, pp. 375-378 (1987).
Lane, T. A., et al., "Paralysis of Phagocyte Migration Due to an Artificial Blood Substitute", Blood, vol. 64, pp. 400-405 (1984).
Kanter; K. R., et al., "Superiority of Perfluorocarbon Cardioplegia Over Blood or Crystalloid Cardioplegia", Circulation, vol. 64, pp. II-75-II-80 (1981).
Harjula, A., et al., "Perfluorocarbon Solution as a Myocardial Preservative", J. Applied Cardiology, vol. 2, pp. 121-136 (1987).
Tokioka, M.D., et al., "Effects of Intracoronary Infusion of Arterial Blood or Fluosol-DA 20% on Regional Myocardial Metabolism and Function During Brief Coronary Artery Occlusions", Laboratory Investigation, vol. 75, pp. 473-481 (1987).
Forman, M. B., et al., "Reduction of Infarct Size with Intracoronary Perfluorochemical in a Canine Preparation of Reperfusion", Circulation, vol. 71, pp. 1060-1068 (1985).
Forman, M. B., et al., "Beneficial Long-Term Effect of Intracoronary Perfluorochemical on Infarct Size and Ventricular Function in a Canine Reperfusion Model", J. Am. Col. of Cardiol., 1082-1080 (May, 1987).
Goodman, R. L., et al., "Perfluorocarbon Emulsions in Canter Therapy: Preliminary Observations on Presently Ava
Allaudeen Hameedsulthan S.
Balasubramanian Mannarsamy
Emanuele R. Martin
Cytrx Corporation
Peabody John
Richter Johann
LandOfFree
Antiinfective polyoxypropylene/polyoxyethylene copolymers and me does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiinfective polyoxypropylene/polyoxyethylene copolymers and me, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiinfective polyoxypropylene/polyoxyethylene copolymers and me will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2357797